ArticleCardiovascular toxicology2025
The Impact of COVID-19 on Graft Vasculopathy and Postoperative Thromboembolism in CABG Patients: A Prospective Controlled Study.
Article in Cardiovascular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of cardiovascular and metabolic comorbidities on severity and outcomes of hospital-acquired sepsis in intensive care patients: a case-control study.BMC infectious diseases · 2026Article
- Elective Cardiopulmonary Bypass (CPB) Surgery After COVID-19: Vasoactive Needs and Early Complications-A Prospective Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is known that COVID-19 patients may experience endothelial cell inflammation, apoptosis, dysfunction, and systemic coagulation disorders. In CABG operations, graft patency plays a crucial role in survival and morbidity. Thrombosis and endothelial cell inflammation in grafts can pose challenges for CABG candidates with a history of COVID-19. This study aimed to evaluate the vasculitic effects of a history of COVID-19 among CABG patients. A total of 94 consecutive patients, including 34 with a history of COVID-19 and 60 without, who were scheduled for CABG at our clinic, were included in the study after informed consent was obtained. Patients with a history of COVID-19 underwent surgery at least 4 weeks after the recovery of infection. Thromboembolic events were monitored throughout the hospital stay, and vascular grafts obtained during surgery were pathologically evaluated for signs of vasculitis and inflammation. All COVID-19 (n = 34) cases were mild. Statistical analysis revealed no significant difference between the groups regarding vein thrombosis/thrombophlebitis (p = 0.626). Additionally, pathological evaluation showed no signs of vasculitis or inflammation. There were also no significant differences in postoperative mortality and morbidity between the two groups (p > 0.05). Based on our findings, undergoing CABG surgery after a four-week recovery period appears to be safe for patients with a history of mild COVID-19, at least in terms of early postoperative vascular outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.